Feedback / Questions
rVIIa-FP (CSL689) - CSL Behring
CSL Behring: R&D Briefing
(CSL Behring)
-
Mar 17, 2015 -
Anticipated initiation of P2/3 trial in patients with hemophilia A & B with inhibitors in H1 2015
Anticipated new P2/3 trial
•
Hemophilia
http://www.csl.com.au/docs/805/134/Investor%20Briefing%20Presentation%20FINAL%202014.pdf
Mar 17, 2015
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.